{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-209934","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2025-09-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.422262+00:00","generated_at":"2026-05-17T06:00:22.180973+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nuvalent completes NDA submission to FDA for zidesamtinib in ROS1-positive NSCLC","bullets":["Completed NDA submission to FDA for zidesamtinib.","Indication: TKI pre-treated advanced ROS1-positive non-small cell lung cancer.","Submission date: September 22, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-209934","json":"https://secwatch.observer/filing/0001193125-25-209934.json","markdown":"https://secwatch.observer/filing/0001193125-25-209934.md","text":"https://secwatch.observer/filing/0001193125-25-209934.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000119312525209934/0001193125-25-209934-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000119312525209934/nuvl-20250922.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:00:22.180973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}